Donanemab

Jul 24, 2026

Summary Alzheimer’s disease treatment has shifted from symptomatic management to disease modification with the emergence of anti-amyloid beta (Aβ) inhibitors that target the root cause by clearing amyloid plaques. Biogen/Eisai’s LEQEMBI and Eli Lilly’s KISUNLA are currently the only Aβ-targeting therapies to...

Feb 12, 2025

Alzheimer’s, the most common type of dementia, particularly with an increasing geriatric population, presents a major global crisis. The disease mostly occurs in sexagenarians, but it may manifest in quadragenarians. It is one of the most prevalent neurodegenerative disorders with a multifactorial pathogenesis. It ...

Jul 08, 2024

The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KISUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanemab...